{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000250","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.913933+00:00","generated_at":"2026-05-30T05:12:17.569378+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance","bullets":["Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.","GAAP diluted EPS $0.38 (vs $0.01 in Q3 2023); non-GAAP diluted EPS $0.83 (vs $0.57, +45.2%).","Non-GAAP adjusted EBITDA $193.7M, or 31.0% of net sales.","Raised FY2024 guidance: revenue $2.49-$2.50B; non-GAAP diluted EPS $2.90-$3.00 (includes $0.09 change in treatment of IPR&D).","Net cash from operations $203.7M; non-GAAP free cash flow $161.7M in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000250","json":"https://secwatch.observer/filing/0001562762-24-000250.json","markdown":"https://secwatch.observer/filing/0001562762-24-000250.md","text":"https://secwatch.observer/filing/0001562762-24-000250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000250/0001562762-24-000250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000250/gmed-20241105x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:12:17.569378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}